Endo Pharma (ENDP) Announces Settlement with LecTec Over Outstanding Patent Litigation
More News related to ENDP
- Endo Pharma (ENDP) Announces Settlement with LecTec Over Outstanding Patent Litigation
- Endo Pharmaceuticals and LecTec Settle Patent Dispute
- Endo Pharma (ENDP) Posts Q3 EPS of $0.63, Misses By 1c; Guides
- Endo Pharmaceuticals Reports Third Quarter 2009 Financial Results and Increases Full-Year Financial Guidance
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
More News related to Corporate News
- Trading Radar for 11/30: Inergy Holdings (NRGP), Golar (GLNG), Omnivision (OVTI), Knightsbridge (VLCCF) Report
- Notable Mergers and Acquisitions of the Day for 11/27: F, S/IPCS, STAR/CSCO, HRAY
- Notable Analyst Rating Changes 11/27: TIF, QLTI Upgraded; FSNM, RGFC Downgraded
- Notable ETF Movers *Special Dubai World Edition* 11/27: UUP Higher; GAF, EEM, FXI, XLF Lower
- Morning Movers 11/27: HEB, FAZ, QLTI Higher; ING, LYG, GNV, GAF Lower
Endo Pharmaceuticals (NASDAQ: ENDP) announced today that it has reached a settlement with LecTec Corporation on outstanding patent litigation related to LecTec's U.S. Patent Nos. 5,536,263 and 5,741,510.
Endo Pharmaceuticals has agreed to make a one-time, $23 million payment for the exclusive license to these two patents for use in the field of prescription pain medicines and treatment. "We are pleased to add these patents to our IP inventory especially as they relate to Lidoderm," said Caroline Manogue, executive vice president and chief legal officer of Endo Pharmaceuticals.
Related Categories
Corporate NewsStocks Mentioned
-0.25Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
